| EPD571 | Effects of COVID-19 to access for services affecting MSMs in Mombasa, Kenya | E-poster | Effects of the COVID-19 on key populations |
| EPE060 | Effects of Dolutegravir on the liver: a meta-analysis involving 37 965 HIV patients | E-poster | Implementation science of scaling up HIV treatment |
| EPF047 | Effects of financial incentives for clinic attendance on economic well-being among adults initiating antiretroviral therapy in Tanzania: a three-arm randomized controlled trial | E-poster | Financial incentives, micro-finance and other economic approaches |
| EPD029 | Effects of HIV-integrated TB interventions on care continuum outcomes for active TB: a systematic review and meta-analysis | E-poster | Mixed methods, integrated approaches and synergies in HIV research and intervention |
| EPB219 | Effects of integrase strand transfer inhibitors (INSTIs) on body mass index and blood pressure in children living with HIV | E-poster | HIV complications and co-morbidities in paediatric and adolescent populations |
| EPD158 | Effects of quality of caregiver-adolescent relationship on HIV, HSV-2 and on pregnancy incidence among young women in rural South Africa enrolled in HPTN 068 | E-poster | Young key populations |
| EPE168 | Effectsof multi month dispensing on viral suppression and continuity in treatment among HIV-infected children aged 2 to 9 years in selected health facilities in Western Kenya | E-poster | Differentiated service delivery for HIV testing, prevention and treatment |
| OAB0302 | Efficacy and safety of dolutegravir plusemtricitabinevs combined antiretroviral therapy for the maintenance of viral suppression: 144-week results of the SIMPL'HIV trial | Oral abstract session with live Q&A | ART in acute, first- and second-line therapies |
| EPB160 | Efficacy and safety of fostemsavir plus optimized background therapy in heavily treatment-experienced adults with HIV-1: week 240 results of the Phase 3 BRIGHTE study | E-poster | ART in highly treatment-experienced persons |
| PESUB21 | Efficacy and safety of switching to Dolutegravir/Lamivudine (DTG/3TC) in treatment-experienced, virologically suppressed PLHIV aged '¥50 years: pooled results from the TANGO and SALSA Studies | Poster exhibition | Regimen simplification and switch studies |